Ginsenoside 20(S)-Rg3 inhibits the Warburg effect through STAT3 pathways in ovarian cancer cells

International Journal of Oncology

Volumn 46, Issue 2, 2015, Pages 775-781

  Li, Jie ^a   Liu, Ting ^a   Zhao, Le ^a   Chen, Wei ^b   Hou, Huilian ^b   Ye, Zhongxue ^a   Li, Xu ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

20(S) R g3; Ovarian cancer; STAT 3; Warburg effect

Indexed keywords

GINSENOSIDE RG 3; HEXOKINASE; PYRUVATE KINASE; PYRUVATE KINASE M2; STAT3 PROTEIN; TYROSINE; UNCLASSIFIED DRUG; GINSENOSIDE; GINSENOSIDE 20S-PROTOPANAXATRIOL; SAPOGENIN; STAT3 PROTEIN, HUMAN;

AEROBIC GLYCOLYSIS; ARTICLE; CANCER INHIBITION; CELLULAR PARAMETERS; CHINESE MEDICINE; CONTROLLED STUDY; FEMALE; GINSENG; GLYCOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; OVARIAN CANCER CELL LINE; OVARY CANCER; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; WARBURG EFFECT; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; MOUSE; OVARIAN NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GINSENOSIDES; GLYCOLYSIS; HUMANS; MICE; OVARIAN NEOPLASMS; SAPOGENINS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84918570803     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2767     Document Type: Article

References (30)

1. Cho KR and Shih IeM: Ovarian cancer. Annu Rev Pathol 4: 287-313, 2009.
2. Swisher EM, Taniguchi T and Karlan BY: Molecular scores to predict ovarian cancer outcomes: a worthy goal, but not ready for prime time. J Natl Cancer Inst 104: 642-645, 2012.
3. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
4. Gillis CN: Panax ginseng pharmacology: a nitric oxide link? Biochem Pharmacol 54: 1-8, 1997.
5. Liao B, Newmark H and Zhou R: Neuroprotective effects of ginseng total saponin and ginsenosides Rb1 and Rg1 on spinal cord neurons in vitro. Exp Neurol 173: 224-234, 2002.
6. Nag SA, Qin JJ, Wang W, Wang MH, Wang H and Zhang R: Ginsenosides as anticancer agents: in vitro and in vivo activities, structure-activity relationships, and molecular mechanisms of action. Front Pharmacol 3: 25, 2012.
7. Lü JM, Yao Q and Chen C: Ginseng compounds: an update on their molecular mechanisms and medical applications. Curr Vasc Pharmacol 7: 293-302, 2009.
8. Lee SY, Kim GT, Roh SH, et al: Proteomic analysis of the anti-cancer effect of 20S-ginsenoside Rg3 in human colon cancer cell lines. Biosci Biotechnol Biochem 73: 811-816, 2009.
9. Mochizuki M, Yoo YC, Matsuzawa K, et al: Inhibitory effect of tumor metastasis in mice by saponins, ginsenoside-R b2, 20(R)-.and 20(S)-ginsenoside-R g3, of red ginseng. Biol Pharm Bull 18: 1197-1202, 1995.
10. Bae EA, Kim EJ, Park JS, Kim HS, Ryu JH and Kim DH: Ginsenosides Rg3 and Rh2 inhibit the activation of AP-1 and protein kinase A pathway in lipopolysaccharide/interferon-gammastimulated BV- 2 microglial cells. Planta Med 72: 627-633, 2006.
11. Keum YS, Han SS, Chun KS, et al: Inhibitory effects of the ginsenoside Rg3 on phorbol ester-induced cyclooxygenase-2 expression, NF- kappaB activation and tumor promotion. Mutat Res 523-524: 75-85, 2003.
12. Cui W, Cheng L, Hu C, Li H, Zhang Y and Chang J: Electrospun poly(L-lactide) fiber with ginsenoside rg3 for inhibiting scar hyperplasia of skin. PLoS One 8: e68771, 2013.
13. Yue PY, Wong DY, Wu PK, et al: The angiosuppressive effects of 20(R)-ginsenoside Rg3. Biochem Pharmacol 72: 437-445, 2006.
14. Warburg O: On the origin of cancer cells. Science 123: 309-314, 1956.
15. Kim JW and Dang CV: Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 66: 8927-8930, 2006.
16. Vander Heiden MG, Cantley LC and Thompson CB: Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029-1033, 2009.
17. Diaz N, Minton S, Cox C, et al: Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res 12: 20-28, 2006.
18. Germain D and Frank DA: Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin Cancer Res 13: 5665-5669, 2007.
19. Wang SW and Sun YM: The IL- 6/JA K/STAT 3 pathway: Potential therapeutic strategies in treating colorectal cancer (Review). Int J Oncol 44: 1032-1040, 2014.
20. Zhu Q, Hu J, Meng H, Shen Y, Zhou J and Zhu Z: S-phase cell cycle arrest, apoptosis, and molecular mechanisms of aplasia ras homolog member I- induced human ovarian cancer SKOV 3 cell lines. Int J Gynecol Cancer 24: 629-634, 2014.
21. Jiang S, Zhang LF, Zhang HW, et al: A novel miR- 155/miR- 143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells. EMBO J 31: 1985-1998, 2012.
22. Demaria M, Giorgi C, Lebiedzinska M, et al: A STAT 3-mediated metabolic switch is involved in tumour transformation and STAT 3 addiction. Aging (Albany NY ) 2: 823-842, 2010.
23. Sawayama H, Ishimoto T, Sugihara H, et al: Clinical impact of the Warburg effect in gastrointestinal cancer (Review). Int J Oncol 45: 1345-1354, 2014.
24. Kiuchi N, Nakajima K, Ichiba M, et al: STAT 3 is required for the gp130-mediated full activation of the c-myc gene. J Exp Med 189: 63-73, 1999.
25. Ando M, Uehara I, Kogure K, et al: Interleukin 6 enhances glycolysis through expression of the glycolytic enzymes hexokinase 2 and 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase-3. J Nippon Med Sch 77: 97-105, 2010.
26. Kim SM, Lee SY, Cho JS, et al: Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF- kappaB. Eur J Pharmacol 631: 1-9, 2010.
27. Lee JY, Jung KH, Morgan MJ, et al: Sensitization of TRAIL- induced cell death by 20(S)-ginsenoside Rg3 via CHOP-mediated DR5 upregulation in human hepatocellular carcinoma cells. Mol Cancer Ther 12: 274-285, 2013.
28. Liu CY, Tseng LM, Su JC, et al: Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT 3 inactivation in human breast cancer cells. Breast Cancer Res 15: R63, 2013.
29. Mathupala SP, Ko YH and Pedersen PL: Hexokinase-2 bound to mitochondria: cancer's stygian link to the 'Warburg Effect' and a pivotal target for effective therapy. Semin Cancer Biol 19: 17-24, 2009.
30. Vander Heiden MG, Lunt SY, Dayton TL, et al: Metabolic pathway alterations that support cell proliferation. Cold Spring Harb Symp Quant Biol 76: 325-334, 2011.